Biocure Technology Inc.
Biocure Technology Inc.
Indice CSE:
Devise:
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE.X)
SEDAR Information
Information d'entreprise
Addresse
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaTéléphone
604-609-7146Courriel
admin@biocuretech.comURL
http://www.biocuretech.comDate d’inscription à la cote
Lundi, mai 10, 2010
Agent de transfert
Computershare Investor Services Inc.Relations avec les investisseurs
Purple Crown Communications Corp.Courriel
Julie@purplecrown.caVérificateur
DMCL Chartered Professional AccountantsCapitalisation
Capitalisation:
10444504Réservé à l'émission:
884059Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
Communiqués de presse
Bulletins
07/05/2010
2010-0503 - New Listing - Gravis Energy Corp. (GVE)
May 7, 2010
The common shares of Gravis Energy Corp. have been approved for listing on CNSX. The Company has 21,294,025 common shares outstanding with a public float of 5.74 million shares.
